You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Human respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. T SS needle protein inhibitors for the treatment of P aeruginosa infection

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: NIAID

    PROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Humanized Monoclonal Antibody to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users

    SBC: AUTOMATE SCIENTIFIC, INC.            Topic: NIDA

    Abstract E cigaretteE ciguse has rapidly proliferated worldwideIt is speculated that E cig use may exceed conventional cigarette use withinyearsCigarette smoking is the leading preventable cause of death and disabilityAs E cigs are a relatively new productstudies are needed to determine their long term detrimental effectssome of which may be similar to the long term detrimental effects of nicotine ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    Three CDKinhibitors were recently approved to treat breast cancerBrCAin combination regimentsDespite significant clinical activitytreatment of BrCA patients with these combinations does not result in a durable responseHencethere is an unmet medical need to develop targeted therapeutic agents which will augment the activity of CDKinhibitors in BrCA and other CDKcyclin D Myc dependent malignanciesA ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Quantitative Biotherapeutic Particle Characterization via Deep Neural Networks

    SBC: Ursa Analytics            Topic: 400

    Project SummaryDespite their many bene ts and common useprotein based drugs can elicit serious adverse side effectsMany of these side effects are believed to be caused by small protein aggregatesOne tool for measuring these particles in a high throughput fashion is Micro ow ImagingMFIMFI is commonly used in both academia and industry to characterize subvisible particlesthosem in sizein protein the ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A scalable system for high throughput, chronic electrophysiology in translational rodent research

    SBC: SPIKEGADGETS, INC.            Topic: 101

    Psychiatric disorders give rise to aberrant patterns of activity within the complex neural circuits of our brainsYetthe exact nature of these abnormal patterns is often unknown to developers of new treatmentsThe goal of this project is to enable circuit oriented research of neuropsychiatric diseases using rodent disease modelsThe long term objective is to catalyze the discovery of new therapeutic ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification

    SBC: Velum Incorporated            Topic: 300

    PROJECT SUMMARY! Peptide therapeutics combine high potency and selectivityand engender fewer side effects than traditional small moleculesThis has fueled interest in peptides filling the gap between `biologicsandaposand small molecules as compounds that have key desired properties from both the other classesThere are however some challengesthe major one being susceptibility to enzyme catalyzed hyd ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a low cost point-of-care device for rapid pathogen detection

    SBC: ELECTRONUCLEICS INC            Topic: NIAID

    Project Summary This project is focused on feasibility testing of a new device based on electromechanical signal transduction for the low cost$in electronicsoptics free and amplification freee gno PCRdetection of DNA RNA at ultralow concentrationThe device addresses the projected $B disease diagnostics market and is well suited for the detection of bacterial pathogens in body fluidsfood and water ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government